4-(5-BROMO-PYRIDIN-2-YL)-4-AZA-TRICYCLO[5.2.2.02,6]UNDEC-8-ENE-3,5-DIONE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	FKENANOSKNCMGT-UHFFFAOYSA-N
Smiles	Brc1ccc(nc1)N2C(=O)C3C4CCC(C=C4)C3C2=O
InChI	InChI=1S/C15H13BrN2O2/c16-10-5-6-11(17-7-10)18-14(19)12-8-1-2-9(4-3-8)13(12)15(18)20/h1-2,5-9,12-13H,3-4H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C15H13BrN2O2
Molecular Weight	333.18
AlogP	2.28
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	1.0
Polar Surface Area	50.27
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	20.0

Assay Description	Organism	Bioactivity
Cytotoxicity against Homo sapiens (human) HONE1 cells after 24 hr by MTT assay	Homo sapiens	None
Cytotoxicity against Homo sapiens (human) HL60 cells after 24 hr by MTT assay	Homo sapiens	200000.0 nM
Cytotoxicity against Homo sapiens (human) NUGC cells after 24 hr by MTT assay	Homo sapiens	200000.0 nM
Cytotoxicity against Homo sapiens (human) Hep2 cells after 24 hr by MTT assay	Homo sapiens	149700.0 nM
Inhibition of iNOS in Mus musculus (mouse) RAW 264.7 cells assessed as inhibition of LPS-induced nitrite production pretreated for 24 hr before stimulation with LPS measured after 18 hr by ELISA	Mus musculus	56.6 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2237480

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

4-(5-BROMO-PYRIDIN-2-YL)-4-AZA-TRICYCLO[5.2.2.0*2,6*]UNDEC-8-ENE-3,5-DIONE

Structure

Physicochemical Descriptors

Cross References

4-(5-BROMO-PYRIDIN-2-YL)-4-AZA-TRICYCLO[5.2.2.02,6]UNDEC-8-ENE-3,5-DIONE